Skip to search formSkip to main contentSkip to account menu

AGS67E

Known as: Anti-CD37 MMAE ADC AGS67E, Anti-CD37 MMAE Antibody-drug Conjugate AGS67E 
An antibody-drug conjugate (ADC) composed of AGS67C, a human anti-CD37 monoclonal antibody covalently linked, via reduced cysteines and a protease… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImmunoconjugatesMonoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract 2709: Evaluation of CD37 expression and binding of AGS67E, an antibody-drug conjugate (ADC) against CD37, on white blood cells (WBCs) collected from phase I non-Hodgkin lymphoma (NHL…
AGS67E is an antibody drug conjugate (ADC) against CD37 conjugated to monomethyl auristatin E (MMAE). CD37 is expressed on normal… 
2016
2016
A first in human experience of the anti-CD37 antibody-drug conjugate AGS67E in lymphoid malignancies.
7549Background: CD37 is a tetraspanin expressed in most B- and T- cell malignancies in previous tumor profiling studies (Pereira… 
2015
2015
A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results
Introduction. AGS67E, a fully human IgG2 antibody conjugated to the anti-tubulin agent MMAE through a cleavable linker, targets… 
2014
2014
Abstract 2650: Ags67e, an anti-cd37 monomethyl auristatin e antibody (mmae) drug conjugate as a potential therapeutic for non-hodgkin's lymphoma, chronic lymphocytic leukemia and acute myeloid…
We have developed AGS67E, an antibody drug conjugate that targets CD37, a tetraspanin highly expressed on malignant B cells, for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)